Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
9
USD
|
-1.85%
|
|
-7.69%
|
+17.19%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
69.72
|
42.98
|
70.12
|
389.1
|
278.8
|
494.2
|
-
|
-
|
Enterprise Value (EV)
1 |
33.48
|
42.98
|
70.12
|
389.1
|
278.8
|
494.2
|
494.2
|
494.2
|
P/E ratio
|
-2.51
x
|
-1.05
x
|
-0.22
x
|
-4.19
x
|
-3.17
x
|
-5.81
x
|
-4.57
x
|
-5.18
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
494
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
494
x
|
EV / EBITDA
|
-
|
-
|
-0.36
x
|
-7.27
x
|
-3.36
x
|
-5.98
x
|
-4.9
x
|
-4.41
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-4.07
x
|
-6.95
x
|
-5.57
x
|
-4.99
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-24.6%
|
-14.4%
|
-17.9%
|
-20%
|
Price to Book
|
-
|
-
|
0.57
x
|
-
|
-
|
1.78
x
|
1.92
x
|
3.23
x
|
Nbr of stocks (in thousands)
|
1,966
|
3,347
|
13,009
|
26,134
|
36,296
|
54,913
|
-
|
-
|
Reference price
2 |
35.46
|
12.84
|
5.390
|
14.89
|
7.680
|
9.000
|
9.000
|
9.000
|
Announcement Date
|
3/10/20
|
3/11/21
|
3/10/22
|
3/22/23
|
3/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
EBITDA
1 |
-
|
-
|
-195
|
-53.5
|
-83.03
|
-82.7
|
-100.9
|
-112.1
|
EBIT
1 |
-27.09
|
-37.44
|
-195
|
-53.5
|
-83.03
|
-89.09
|
-107.2
|
-118.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-11,844.28%
|
Earnings before Tax (EBT)
1 |
-26.29
|
-37.3
|
-194.9
|
-51.83
|
-72.89
|
-79.64
|
-101.3
|
-113.9
|
Net income
1 |
-26.29
|
-37.3
|
-194.9
|
-51.83
|
-72.89
|
-79.64
|
-101.3
|
-113.9
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-11,389.76%
|
EPS
2 |
-14.10
|
-12.18
|
-24.58
|
-3.550
|
-2.420
|
-1.548
|
-1.968
|
-1.738
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-68.47
|
-71.1
|
-88.7
|
-99
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-9,900%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/11/21
|
3/10/22
|
3/22/23
|
3/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-9.508
|
-15.38
|
-11.45
|
-12.39
|
-14.29
|
-13.49
|
-15.1
|
-20.24
|
-34.2
|
-19.3
|
-20.3
|
-21.4
|
-21.7
|
-
|
EBIT
1 |
-7.898
|
-9.508
|
-15.38
|
-11.45
|
-12.39
|
-14.29
|
-13.49
|
-15.1
|
-20.24
|
-34.2
|
-20.11
|
-21.64
|
-23.64
|
-25.3
|
-27.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-7.871
|
-9.491
|
-15.32
|
-11.25
|
-12
|
-13.26
|
-11.19
|
-12.57
|
-17.73
|
-31.41
|
-17.7
|
-18.95
|
-20.86
|
-22.14
|
-25.06
|
Net income
1 |
-7.871
|
-9.491
|
-15.32
|
-11.25
|
-12
|
-13.26
|
-11.19
|
-12.57
|
-17.73
|
-31.41
|
-17.7
|
-18.95
|
-20.86
|
-22.14
|
-25.06
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6100
|
-0.7300
|
-1.180
|
-0.8600
|
-0.8700
|
-0.7200
|
-0.4000
|
-0.4500
|
-0.6300
|
-0.9400
|
-0.3640
|
-0.3640
|
-0.4000
|
-0.4160
|
-0.4400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/10/22
|
5/12/22
|
8/9/22
|
11/10/22
|
3/22/23
|
5/11/23
|
8/7/23
|
11/13/23
|
3/4/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
36.2
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-68.5
|
-71.1
|
-88.7
|
-99
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
9.400
|
-
|
-
|
5.070
|
4.680
|
2.790
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
0.02
|
-
|
0.03
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/11/21
|
3/10/22
|
3/22/23
|
3/4/24
|
-
|
-
|
-
|
Average target price
25.29
USD Spread / Average Target +180.95% Consensus |
1st Jan change
|
Capi.
|
---|
| +17.19% | 494M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|